

REMARKS

Status

Claims 1-7 and 9-20 will be pending upon entry of the present amendment. No new matter will be added upon entry of the amendments.

Response to Rejections

Applicants appreciate Examiner's acknowledgement that the previous 102 rejection has been overcome by the deletion of "pyrimidyl" in A.

The rejection of Claims 1-7 and 14-21, now 1-7 and 14-19, under 35 U.S.C. §112, 1st paragraph has been obviated by appropriate amendment.

Applicants have limited the presently claimed invention to the quinazolin-4-ones shown below, wherein ring G is a pyridyl ring, ring A is a phenyl or pyridyl ring and B is phenyl or 5-6 membered heterocycle. In addition to the arguments presented in the response of November 21, 2006, Applicants submit that it is well within the skill of an organic chemist to select and/or prepare appropriate starting materials to form the desired A-B intermediates and follow the teaching of the present invention to obtain the compounds of formula I. In light of the currently amended claims, the high level of skill in the art of organic synthesis, the plethora of factor Xa patents (and publications), and the high level of skill in the selection and clinical development of factor Xa inhibitors, Applicants submit that the presently amended claims are enabled. Withdrawal of the §112, 1st paragraph, rejection is respectfully requested.

The rejection of Claims 1-6, 14-19, and 21, now 1-6 and 14-19 under 35 U.S.C. §112, 2nd paragraph has been obviated by appropriate amendment. The following paragraph designations refer to those provided on pages 6-7 of the Office Action.

a. Applicants have removed the phrase "*alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy*".

Withdrawal of this rejection is respectfully requested.

b. The reference to Z in the definition of B has been removed. Withdrawal of this rejection is respectfully requested.

c. Claim 21 has been cancelled. Withdrawal of this rejection is respectfully requested.

Restriction Response

With respect to withdrawn claims 9-13, Applicants respectfully request rejoinder of these claims once allowable subject matter has been found in claim 1, in accordance with the provisions of MPEP § 821.04.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Respectfully submitted,

Date: February 22, 2007

/jing g. sun/
Jing G. Sun, Ph.D.
Registration No. 45,914
Telephone No. (609) 252-3791
Facsimile No. (609) 252-4526

Please forward all future written correspondence relating to this application to:

Louis J. Wille
Patent Department
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000